Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Study of Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

NCT07539155 is registered in ClinicalTrials.gov with University of Arkansas as lead sponsor.

NCT NCT07539155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07539155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Study of Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
Lead sponsor
University of Arkansas
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 26, 2026
Completion date
August 31, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable/unresectable pancreatic cancer, non metastatic pancreatic cancer